The DOI matches its Crossref record.
Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder: An Open-Label Trial
Abstract
BACKGROUND: Dissociative phenomena, including flashbacks, are common in patients with borderline personality disorder and posttraumatic stress disorder (PTSD). Although dissociative symptoms can be severe and may interfere with psychotherapy, there is no established pharmacotherapy for these symptoms. Evidence suggests that alterations of the endogenous opiate system contribute to dissociative symptoms in patients with borderline personality disorder and PTSD. METHOD: We treated 2 groups of female borderline personality disorder patients (N = 13, with an overlap of 5 patients between the 2 groups; all met the diagnostic criteria of DSM-IV and the revised Diagnostic Interview for Borderline Patients) who experienced prominent dissociative phenomena including flashbacks with the nonselective opiate receptor antagonist naltrexone, 25 to 100 mg q.i.d., for at least 2 weeks. A self-rated questionnaire measuring dissociation, analgesia, tonic immobility, and tension (DAISS) was applied to 9 patients, who completed it for 7 consecutive days before and during treatment with naltrexone. In addition, 9 patients (with an overlap of 5 patients from the other group) completed a flashback protocol. RESULTS: DAISS scores reflected a highly significant reduction of the duration and the intensity of dissociative phenomena and tonic immobility as well as a marked reduction in analgesia during treatment with naltrexone. Six of 9 patients reported a decrease in the mean number of flashbacks per day. CONCLUSION: These observations support the hypothesis that an increased activity of the opioid system contributes to dissociative symptoms, including flashbacks, in borderline personality disorder and suggest that these symptoms may respond to treatment with opiate antagonists. In view of these results, a placebo-controlled, double-blind study to assess the potential benefit of naltrexone in a more rigorous way appears justified.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Longitudinal and case series studies of naltrexone and nalmefene in depersonalization disorder, borderline personality disorder, and PTSD also support opioid antagonist administration for reduced dissociative symptoms [116–119].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [117]
In the citing paper
“Finally, a handful of studies report successful reductions in dissociative symptoms, including depersonalization, following treatment with opioid-receptor antagonists (e.g., naloxone and naltrexone) among individuals with depersonalization disorder (Nuller et al., 2001;Simeon and Knutelska, 2005), and BPD (Bohus et al., 1999;Schmahl et al., 2012; but see Philipsen et al., 2004).”
From A review of the relation between dissociation, memory, executive functioning and social cognition in military members and civilians with neuropsychiatric conditions (2016) · cites this paper as Bohus et al., 1999
Citations
Cites
Still being checked.
Cited by
Borderline personality disorder
Lieb, K., Zanarini, M. C., Schmahl, C., Linehan, M. M., & Bohus, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16770-6 · Cited by 1,369
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Association Between Mental Health Disorders, Problem Drug Use, and Regular Prescription Opioid Use
Sullivan, M. D., Edlund, M. J., Zhang, L., Unützer, J., & Wells, K. B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2087 · Cited by 434
Forbes, D., Creamer, M., Phelps, A., Bryant, R., McFarlane, A., Devilly, G. J., Matthews, L., Raphael, B., Doran, C., Merlin, T., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449161 · Cited by 335
Pharmacological interventions for borderline personality disorder
Stoffers, J., Völlm, B. A., Rücker, G., Timmer, A., Huband, N., & Lieb, K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005653.pub2 · Cited by 302
Metadata
- Authors
- Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Böhme, R., & Schmahl, C. G.
- Affiliations
- University of Freiburg (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1999-09-15
- Volume
- 60
- Issue
- 9
- Pages
- 598-603
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1990256375
- Cited by
- 153
- References
- 0
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 6 · 2013: 8 · 2012: 6
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- naltrexone, borderline personality disorder, dissociative symptoms, flashbacks, post-traumatic stress disorder, opioid system, opioid antagonists, tonic immobility, analgesia, dissociation
- MeSH terms
- Adolescent, Adult, Borderline Personality Disorder, Dissociative Disorders, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Germany, Humans, Middle Aged, Naltrexone, Narcotic Antagonists, Personality Inventory, Psychiatric Status Rating Scales, Severity of Illness Index, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder: An Open-Label Trial. https://app.cochat.ai/papers/10.4088/jcp.v60n0906
- The paper
- Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Böhme, R., & Schmahl, C. G. (1999). Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder: An Open-Label Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v60n0906
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.